slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 201,871-201,900
Pages 10,126
Rows per page 30
Component
201,871-201,900 of 303,780
17
Includes Kaplan-Meier survival curve and comparative efficacy tables.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
18
Includes a timeline of biopsy (Bx) and treatment, and paired dot plots showing pre/post treatment changes in CD68+ and CD3+ cell counts.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
19
Spider plot (swimmer plot variant) showing individual patient tumor response trajectories.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
20
The slide uses a two-part structure: a value proposition box followed by a list of upcoming milestones.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
21
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
22
The slide uses a biological process diagram to illustrate the mechanism of action.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
23
Includes statistical significance markers (*, **, ***) and TGI (Tumor Growth Inhibition) percentages.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
24
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
26
The slide uses a Gantt-style timeline to map clinical trial events (P2 data, FDA meetings, enrollment) against a calendar axis from 2021 to 2023.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
27
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
01
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations 1 hit
02
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations 1 hit
03
Comparison of Tmax metrics and safety profiles for single vs repeat dosing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses callout boxes connected to specific organs to detail symptom frequency and clinical manifestations.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Agitate (Make it worse)1 hit
05
The chart uses a dual-line comparison to show the divergence in risk outcomes based on treatment timing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
07
Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
08
Box plot showing baseline adjusted epinephrine Tmax.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
09
Shows rapid onset of therapeutic benefits for AQST-109.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
11
The chart shows box plots for baseline adjusted Epinephrine Cmax, highlighting differences in drug exposure between the two treatment groups.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
12
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
13
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
14
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations 1 hit
01
Includes company logo, ticker symbol, and a representative photo of a patient.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
02
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
03
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
04
The slide uses academic citations to establish the clinical relevance of the target protein.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a scientific diagram of the signaling pathway and references to academic literature.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Includes a bifurcation diagram illustrating the relationship between SNAIL and ZEB mRNA levels in different cell phenotypes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit